Main Takeaways
- Nestlé Health Science is set to acquire the global rights to Vowst from Seres Therapeutics, giving it full control over the product's worldwide development and commercialization.
- Vowst has been successfully marketed in the US since June 2023 and fits within Nestlé's expertise in gastrointestinal treatments.
- The acquisition includes a focus on maintaining Vowst’s safety and efficacy, with plans to further develop the product and expand its availability globally while addressing potential safety concerns.
There are anticipated benefits of Nestlé's expertise and resources for the Vowst product and its availability to patients, “With our Pharma portfolio focused in gastro-intestinal disorders, we can further leverage our commercial footprint and expertise to continue raising awareness on the impact of rCDI. Since its launch, we observed increased interest from the broader healthcare community in safe and effective solutions to alleviate the burden of rCDI,” Perugini states.
Although, it is important to remember that Vowst is indicated for preventing the recurrence of CDI in individuals aged 18 and older following antibacterial treatment for rCDI, and is not intended for the treatment of CDI.1
Saftey Information
Vowst is derived from human fecal matter, which may pose a risk of transmitting infectious agents. Vowst may also contain food allergens, though the risk of adverse reactions is not fully known. Common adverse reactions (reported in 5% or more of participants) include abdominal distension (31.1%), fatigue (22.2%), constipation (14.4%), chills (11.1%), and diarrhea (10.0%). VOWST should not be administered concurrently with antibacterials.1
To address safety concerns, Perugini states, “At Nestlé Health Science, the safety, quality and efficacy of our products are of utmost importance and priority: patients first! We remain confident in the safety and efficacy of Vowst, as demonstrated in the clinical data, and will continue to closely monitor any potential future risks.”
In June 2024, Nestlé bought Vowst,2 but this new agreement grants Nestlé full control over Vowst’s development, manufacturing, and distribution worldwide. This shift from a regional to a global scope reflects a broader strategic approach, enabling Nestlé to manage Vowst on an international level and integrate it into its global operations. This transition illustrates Nestlé's move from a market-specific acquisition to a comprehensive, global management strategy for Vowst.
References
